

Please try another search
For the three months ended 31 March 2022, Epizyme Inc revenues increased 14% to $8.7M. Net loss decreased 21% to $55.5M. Revenues reflect Product revenue, net increase of 40% to $8.7M. Lower net loss reflects General and administrative - Balancing decrease of 25% to $23.7M (expense), Research and development - Balancing decrease of 8% to $28M (expense), Stock-based Compensation in SGA decrease of 27% to $3.5M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 8.7 | 11.58 | 5.2 | 13.01 |
Gross Profit | 6.06 | 8.43 | 3.2 | 10.52 |
Operating Income | -50.93 | -51.29 | -64.14 | -58.23 |
Net Income | -55.51 | -50.65 | -65.83 | -64.36 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 312.19 | 289 | 332.27 | 352.55 |
Total Liabilities | 301.06 | 309.69 | 316.89 | 284.92 |
Total Equity | 11.12 | -20.69 | 15.38 | 67.63 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -59.19 | -226.85 | -174.89 | -132.25 |
Cash From Investing Activities | -44.19 | 125.48 | 107.3 | 40.66 |
Cash From Financing Activities | 82.46 | 31.49 | 23.89 | 3.54 |
Net Change in Cash | -20.91 | -69.88 | -43.7 | -88.05 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review